Oct 14, 2015_Bone and Mineral Metabolism PR

Related Posts

• Novartis’ Cosentyx Takes the Wind Out of Stelara’s Sails in Psoriatic Arthritis Market

  New findings in a recent study by Spherix Global Insights, RealWorld Dynamix™: Biologic and Otezla Switching in PsA, indicate an…

• User Base for Novartis’ Cosentyx in Psoriatic Arthritis Significantly Expands as Rheumatologists Report High Satisfaction

  Download Report Overview At nearly six months post launch, three-quarters of US rheumatologists report having prescribed Cosentyx, a significant increase…

• Psoriasis and Psoriatic Arthritis Markets Undergo Big Changes as IL-17s, such as Novartis’ Cosentyx and Lilly’s Taltz, Increase Penetration

  IL-17s stop Janssen's Stelara in its tracks and while Cosentyx holds out as the only approved IL-17 in PsA, competition…